AOD-9604

Original price was: $90.00.Current price is: $63.00.

AOD-9604 is a synthetic hexadecapeptide fragment corresponding to residues 176–191 of human growth hormone. It selectively stimulates adipocyte lipolysis by upregulating β₃-adrenergic receptors and inhibiting lipoprotein lipase, while sparing IGF-1 receptor activation. The peptide demonstrates oral bioavailability and reduces weight gain in rodent models without altering blood glucose levels.
Description

Product details

Amino Acid Sequence

Tyr–Leu–Arg–Ile–Val–Gln–Cys–Arg–Ser–Val–Glu–Gly–Ser–Cys–Gly–Phe

Molecular Formula

C₇₈H₁₂₃N₂₃O₂₃S₂

Molecular Weight

1815.1 g/mol

PubChem CID

71300630

CAS Number

221231-10-3

Vial Size

3ml

Contents

Lyophilized powder, white/off-white color

Mechanism of action

β₃-Adrenergic Receptor–Mediated Lipolysis

AOD-9604 upregulates β₃-adrenergic receptor expression in adipocytes, increasing intracellular cAMP and activating hormone-sensitive lipase for fatty-acid mobilization

Lipoprotein Lipase Inhibition

The peptide directly inhibits adipose tissue lipoprotein lipase activity, shifting the balance toward enhanced fat breakdown over storage.

Oral Bioavailability

In obese Zucker rats, once-daily oral dosing (500 µg/kg) achieved systemic exposure and a >50% reduction in weight gain, demonstrating effective gastrointestinal absorption

Storage & handling

Storage:

Store the lyophilized vial in a cool, dry area protected from direct sunlight.
Legal Disclaimer

All products on this site are for research and development, laboratory, or analytical use only; they are not for human consumption, medical, diagnostic, cosmetic, veterinary, or any other non-research application. The statements and products have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Honest Peptide is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, nor an outsourcing facility as defined under section 503B.